Even more, PKR gene silencing (RNAi) or treatment with the specific PKR inhibitor, C16, significantly inhibits PKR activation in neuroblastoma cells and inhibits downstream activities of caspase-3 and caspase-8. The gene discussed is CASP3; the disease is neuroblastoma.